Injection site reactions with Ozempic®

How often it happened in the trials

Each official document reports injection site reactions in a slightly different way. The US label gives one figure across the Ozempic® groups of its placebo-controlled trials. Europe gives a figure for each dose from its larger trial pool. Canada reports the same placebo-controlled figure as the US and adds the placebo rate ^[1][2][3].

What the placebo figure tells you

The Canadian figure is a useful reminder that a needle under the skin can cause redness or discomfort whatever is in it. In those trials, placebo injections produced reactions slightly more often than Ozempic® did ^[3]. None of the documents gives how long the reactions lasted; Europe only says they were usually mild ^[2].

For scale, nausea in the same US trials was reported by 15.8% to 20.3% of treated adults, roughly a hundred times more often than an injection site reaction ^[1].

What a class-wide meta-analysis found

A 2026 study combined two approaches. A meta-analysis of 14 randomised trials with 4,861 patients found injection site reactions more frequent with GLP-1 medicines as a group than with comparators (risk ratio 3.55). A separate look at the US FDA adverse event reporting system flagged possible signals for injection-site bleeding with exenatide and dulaglutide. Wider skin reactions were infrequent and not significantly raised ^[5].

The trial part pooled several GLP-1 medicines, and reporting-system data show which reactions are reported more often than expected, not how often they happen or whether the medicine caused them ^[5]. For Ozempic® specifically, the three product documents above remain the best guide.

Where the label says to inject

• Into the fatty layer under the skin (subcutaneously) of the belly, thighs or upper arms; the Medication Guide adds that it must not go into a muscle or a vein ^[1].
• A different injection site each week when using the same body region; Europe notes the site can change without any dose adjustment ^[1][2].
• If you also use insulin, the two go in as separate injections and are never mixed. They may share a body region, but the label says the injections should not sit right next to each other ^[1].
• Before each use, the solution should look clear and colourless; the label says not to use it if particles or colour are visible ^[1].

What the pen and syringe instructions describe

The pen instructions describe wiping the chosen site with an alcohol swab and letting the skin dry, using a new needle every time, and keeping the dose button pressed for 6 seconds after the counter reaches 0 so the full dose is delivered. NovoFine® Plus 32G 4 mm needles come in the pen carton. Section 5.4 is firm that one pen belongs to one person: swapping the needle does not make sharing safe, because blood-borne infections can still pass between users ^[1].

Ozempic® also comes as single-dose prefilled syringes. Their instructions describe pinching a fold of skin, inserting the needle fully at a 45-degree angle, and choosing the belly (keeping about 2 inches, roughly 5 cm, clear of the navel), the thighs, or the back of the upper arm when someone else can help. They also say not to warm a syringe with hot water or a microwave, and not to use one that has been frozen ^[1].

When skin changes may be an allergy

A reaction confined to the injection spot is different from an allergic reaction. Section 5.8 reports serious hypersensitivity reactions, including anaphylaxis and angioedema, in people treated with Ozempic®, and section 6.2 lists rash and hives among reports received after approval ^[1]. Europe classes hypersensitivity, a grouped term that covers rash and hives, as uncommon and anaphylactic reactions as rare ^[2].

For an allergy, the Medication Guide’s instruction is to stop Ozempic® and get medical help at once. The signs it lists are a swollen face, lips, tongue or throat; difficulty breathing or swallowing; severe itching or rash; fainting or dizziness; and a very fast heartbeat ^[1].

Antibodies to semaglutide

Section 12.6 of the US label reports that 1% of Ozempic®-treated adults in the glycemic control trials developed antibodies to semaglutide, and 0.6% had antibodies that also reacted with natural GLP-1; the label calls their neutralising effect uncertain ^[1]. Europe puts the share testing positive at any point at 1% to 3% and says no one had neutralising antibodies at the end of the trials ^[2]. Neither document links these antibodies to injection site reactions.

Why it may happen, and what else it could be

What the documents support: any subcutaneous injection can cause local discomfort or redness, and the placebo figure in Canada shows this happens without the active medicine too ^[3]. Europe notes that, like other protein and peptide medicines, semaglutide can trigger antibodies, though it does not tie this to local reactions ^[2].

Other explanations worth considering: a little bleeding or a bruise from the needle itself, which the patient page addresses directly ^[4]; an insulin injection given right next to the Ozempic® site ^[1]; or a rash that spreads beyond the spot, which belongs with the allergy signs above rather than with local reactions ^[1].

What may help

• Rotate sites every week and avoid reusing one spot, as the label and the patient page both ask ^[1][4].
• Follow the instructions for cleaning the skin, letting it dry and using a new needle each time ^[1].
• If a little blood appears, press lightly with gauze or cotton and do not rub ^[1][4].
• Talk to your healthcare professional about irritation or a reaction at the injection site that bothers you or does not go away ^[4].
• Ask your prescriber, nurse or pharmacist to watch you inject if you are unsure about technique; the Medication Guide says your provider should show you before the first dose ^[1].

Details worth writing down

If a site reaction does happen, note which area and side you used, how soon the redness or discomfort started, how large it was, how long it lasted and whether it came back at the same site. A photo can help too. Patterns tied to one site are much easier to spot when every injection has a recorded location.

Ozempic® and NovoFine® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.